Effect of Sacubitril-Valsartan on Cardiac Structure and Function
Key facts
- Where
- Rochester, United StatesSee the site
- Phase
- Phase 3
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Amanda WozniakTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06693674
- Record updated
- 9 October 2026
- Original description
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.Read full original descriptionShow less
Effect of Sacubitril-Valsartan on Cardiac Structure and Function in Adults With Congenital Heart Disease
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
Inclusion: Congenital Heart Disease Diagnosis; Age 18 or Older.
Exclusion: History of angioedema related to previous ACE or ARB therapy; Drug Therapies; Amifostine; Droperidol; Dantrolene; CYP3A4 Inhibitors; Obinutuzumab; Aliskiren; Lithium; Sparsentan; ACE inhibitor; ARB; ARNI; Patients diagnosed with diabetes using Aliskiren,; Stage IV chronic kidney disease defined as creatinine clearance <30 ml/min; Hyperkalemia defined as serum potassium >5.2 mmol/l,; Hypotension defined as systolic blood pressure <100 mmHg,; Pregnancy.